

## STALLERGENES GREER TO REPORT FULL YEAR FINANCIAL RESULTS ON 21 MARCH 2019

**London (UK), March 7, 2019** – Stallergenes Greer, a biopharmaceutical company specializing in treatments for respiratory allergies, today announced it will report financial results for the full fiscal year ended 31 December 2018 on 21 March 2019, before market hours. The Company's management will host a live conference call and audio webcast at 10:30 am London / 11:30 am Paris / 6:30 am Boston that same day to discuss the FY 2018 results.

Members of the financial community may access the conference call through the dial-in information provided on the company's website, at <http://stallergenesgreer.com/financial-calendar-events>. The live audio webcast will be accessible to the general public via the following link: <https://edge.media-server.com/m6/p/vtdehysm> Participants are asked to connect at least 15 minutes prior to the conference call to register, download and install any necessary audio software. The webcast and conference call will be archived for one year.

### ABOUT STALLERGENES GREER PLC

Headquartered in London (UK), Stallergenes Greer plc is a global healthcare company specialising in the diagnosis and treatment of allergies through the development and commercialisation of allergy immunotherapy products and services. Stallergenes Greer plc is the parent company of GREER Laboratories, Inc. (whose registered office is in the United States) and Stallergenes SAS (whose registered office is in France).

### TRADING INFORMATION

Name: Stallergenes Greer  
ISIN: GB00BZ21RF93 1 - Ticker: STAGR  
ICB Classification: 4577  
LEI: 213800CYVZA7GJQEME86  
Market: Euronext Paris regulated market

Additional information is available at <http://www.stallergenesgreer.com>.

This document (including information incorporated by reference in this document), oral statements made and other information published by the Company contain statements that are or may be forward-looking with respect to the financial condition and/or results of operations and businesses of the Company. These statements can be identified by the use of forward-looking terminology such as "believe," "expects," "project," "estimated," "forecast," "should," "plan," "may," "will," or the negative of any of these, or other variations thereof, or comparable terminology indicating expectations or beliefs concerning future events. These forward-looking statements include risk and uncertainty because they relate to events and depend on circumstances that will occur in the future. Without being exhaustive, such factors include economic situations and business conditions, including legal and product evaluation issues, fluctuations in currencies and demand, and changes in competitive factors. These and other factors are more fully described in the Company's 2018 annual report published on 21 March 2019 on the Company's website [www.stallergenesgreer.com](http://www.stallergenesgreer.com). Actual results may differ materially from those set forth in the forward-looking statements, due to these and other various factors. Save as required by applicable law, neither the Company nor any other person assumes any obligation to update these forward-looking statements or to notify any person of any such update.

### CONTACTS

#### Investor Relations

Youssef Abbas  
Tel: +33 1 55 59 78 43  
E-mail: [youssef.abbas@stallergenesgreer.com](mailto:youssef.abbas@stallergenesgreer.com)

#### Investor Relations Agency

FTI Consulting  
Arnaud de Cheffontaines  
Tel: +33 1 47 03 69 48  
E-mail: [stallergenesgreer@fticonsulting.com](mailto:stallergenesgreer@fticonsulting.com)

#### Communications

Catherine Kress  
Tel: +33 1 55 59 26 05  
E-mail: [catherine.kress@stallergenesgreer.com](mailto:catherine.kress@stallergenesgreer.com)

#### Media Relations Agency

Havas Paris (Europe)  
Samuel Rousseau  
Tel: +33 6 77 88 32 43  
E-mail: [samuel.rousseau@havas.com](mailto:samuel.rousseau@havas.com)